Cargando…
Stevens-Johnson Syndrome Induced by Vandetanib
Vandetanib is a once-daily oral anticancer drug that selectively inhibits key signaling pathways in cancer by targeting vascular endothelial growth factor receptors, epidermal growth factor receptors tyrosine kinase, and rearranged during transfection-dependent tumor cell proliferation and survival....
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Dermatological Association; The Korean Society for Investigative Dermatology
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3276793/ https://www.ncbi.nlm.nih.gov/pubmed/22346274 http://dx.doi.org/10.5021/ad.2011.23.S3.S343 |
_version_ | 1782223406354137088 |
---|---|
author | Yoon, Jimi Oh, Chee Won Kim, Chi Yeon |
author_facet | Yoon, Jimi Oh, Chee Won Kim, Chi Yeon |
author_sort | Yoon, Jimi |
collection | PubMed |
description | Vandetanib is a once-daily oral anticancer drug that selectively inhibits key signaling pathways in cancer by targeting vascular endothelial growth factor receptors, epidermal growth factor receptors tyrosine kinase, and rearranged during transfection-dependent tumor cell proliferation and survival. The most frequently reported adverse events attributed to vandetanib include diarrhea, elevated aminotransferase, asymptomatic corrected QT interval prolongation, and hypertension. Though a number of randomized, doubleblind studies, including cutaneous adverse events attributed to vandetanib, have been reported along with these general symptoms, no case of Stevens-Johnson syndrome (SJS) has been reported. This paper demonstrates a case of SJS induced by vandetanib. |
format | Online Article Text |
id | pubmed-3276793 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Korean Dermatological Association; The Korean Society for Investigative Dermatology |
record_format | MEDLINE/PubMed |
spelling | pubmed-32767932012-02-16 Stevens-Johnson Syndrome Induced by Vandetanib Yoon, Jimi Oh, Chee Won Kim, Chi Yeon Ann Dermatol Case Report Vandetanib is a once-daily oral anticancer drug that selectively inhibits key signaling pathways in cancer by targeting vascular endothelial growth factor receptors, epidermal growth factor receptors tyrosine kinase, and rearranged during transfection-dependent tumor cell proliferation and survival. The most frequently reported adverse events attributed to vandetanib include diarrhea, elevated aminotransferase, asymptomatic corrected QT interval prolongation, and hypertension. Though a number of randomized, doubleblind studies, including cutaneous adverse events attributed to vandetanib, have been reported along with these general symptoms, no case of Stevens-Johnson syndrome (SJS) has been reported. This paper demonstrates a case of SJS induced by vandetanib. Korean Dermatological Association; The Korean Society for Investigative Dermatology 2011-12 2011-12-27 /pmc/articles/PMC3276793/ /pubmed/22346274 http://dx.doi.org/10.5021/ad.2011.23.S3.S343 Text en Copyright © 2011 Korean Dermatological Association; The Korean Society for Investigative Dermatology http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Yoon, Jimi Oh, Chee Won Kim, Chi Yeon Stevens-Johnson Syndrome Induced by Vandetanib |
title | Stevens-Johnson Syndrome Induced by Vandetanib |
title_full | Stevens-Johnson Syndrome Induced by Vandetanib |
title_fullStr | Stevens-Johnson Syndrome Induced by Vandetanib |
title_full_unstemmed | Stevens-Johnson Syndrome Induced by Vandetanib |
title_short | Stevens-Johnson Syndrome Induced by Vandetanib |
title_sort | stevens-johnson syndrome induced by vandetanib |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3276793/ https://www.ncbi.nlm.nih.gov/pubmed/22346274 http://dx.doi.org/10.5021/ad.2011.23.S3.S343 |
work_keys_str_mv | AT yoonjimi stevensjohnsonsyndromeinducedbyvandetanib AT ohcheewon stevensjohnsonsyndromeinducedbyvandetanib AT kimchiyeon stevensjohnsonsyndromeinducedbyvandetanib |